论文部分内容阅读
2005年,首个肠促胰素类药物艾塞那肽被美国食品药品监督管理局(FDA)批准上市,随后基于胰高血糖素样肽1(GLP-1)的药物研发和临床应用进入快速发展阶段。目前,我国已经上市了2种GLP-1受体激动剂和5种二肽基肽酶Ⅳ(DPP–4)抑制剂,为方便临床医生掌握这两类药物的基本知识和临床应用,中华医学会糖尿病学分会在2014年发布了《基于胰高血糖素样肽1降糖药物的临床应用共识》。
In 2005, exenatide, the first incretin, was approved by the US Food and Drug Administration (FDA) for approval and subsequently progressed rapidly based on drug development and clinical use of glucagon-like peptide 1 (GLP-1) development stage. At present, two kinds of GLP-1 receptor agonists and five DPP-4 inhibitors have been listed in our country. To facilitate clinicians to master the basic knowledge and clinical application of these two drugs, The Diabetes Unit credits the 2014 Consensus on Clinical Practice Based on Glucagon-like Peptide 1 Hypoglycemic Drugs.